ERBB2 and breast carcinoma: Accumulating evidence suggests that PI3K/AKT/mTOR promote breast cancer cell survival and resistance to chemotherapeutics such as trastuzumab (a blocking antibody to Her-2) and tamoxifen (Hynes and Dey, 2009; Ghayad et al, 2010).